Segova New Generation

Professor Ljubic and his team have developed innovations in the ovaries and testes regeneration programme.

SEGOVA New Generation (NG) is the most complete, available medical biotechnological programme for rejuvenating and improving gonadal function. The new generation of the rejuvenation programme has evolved due to the implementation of the most recent findings and novel technologies in clinical practice.

SEGOVA NG implies shortened procedure, which demands spending only one day in the hospital. This approach is possible due to the application of modern work techniques during tissue retransplantation and the introduction of novel scaffolds (autologous bio-regenerative fibrin) which maintain retransplantated tissue and stem cells at the desired place within the ovarian or testicular tissue.

SEGOVA NG in its present form implies the following:

  • Preparation – one or more days or weeks, including analyses of hormones, immunological status, infections, metabolism, vitamins, microelements and genetics.
  • Performing of Procedure – during the one-day stay in the hospital, blood is drawn from the patient to isolate growth factors, a biopsy of iliac bone and aspiration of bone marrow with the separation of stem cells in bone marrow aspirate concentrate and plasma for exosomes preparation, laparoscopy with tangential ovarian cortex biopsy with the administration of autologous haemostatics instead of classical destructive techniques, micro fragmentation of ovarian tissue submerged in mediums with growth factors, formation of subcortical tunnels for tissue retransplantation, application of scaffold and consequently micro fragmented ovarian tissue with mesenchymal stem cells in the adequate subcortical spaces, the closure of the tunnel with the bio-regenerative fibrin.
  • Follow-up – monthly or annual ultrasound and laboratory follow-up, with suggestions or implementation of advanced in vitro fertilisation techniques

SEGOVA is a biological regenerative therapy which has been done in hundreds of patients with the 15 % of success.

Professor Ljubic and his team have already performed SEGOVA NG in the first series of patients in collaboration with IASO Hospital in Cyprus.